XML 45 R34.htm IDEA: XBRL DOCUMENT v3.25.3
Revenue - Narrative (Details)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2025
USD ($)
Sep. 30, 2024
USD ($)
Sep. 30, 2025
USD ($)
segment
Sep. 30, 2024
USD ($)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]        
Number of reportable segments | segment     4  
Net sales $ 11,369 $ 10,635 $ 32,869 $ 30,976
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-10-01        
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]        
Percentage of remaining performance obligation expected to be recognized in period     54.00%  
Expected timing of satisfaction period (in months) 24 months   24 months  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2027-10-01        
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]        
Percentage of remaining performance obligation expected to be recognized in period     17.00%  
Expected timing of satisfaction period (in months) 12 months   12 months  
Diagnostic Products        
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]        
Remaining performance obligations $ 6,000   $ 6,000  
Diagnostic Products | COVID-19 Testing        
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]        
Net sales 69 $ 265 208 $ 571
Medical Devices        
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]        
Remaining performance obligations $ 436   $ 436